Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24941854 | 0.88 | HRH3 (0.51) | HRH3ALDH1A1CYP2D6KDM5A | |
| SCHEMBL8259460 | 0.85 | HRH3 (0.47) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL8263831 | 0.85 | HRH3 (0.50) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL12258709 | 0.85 | HRH3 (0.50) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL12258724 | 0.85 | HRH3 (0.50) | HRH3ALDH1A1CYP2D6CA1CA2 | |
| SCHEMBL12026487 | 0.85 | ALDH1A1 (0.54) | HRH3ALDH1A1CYP2D6 | |
| SCHEMBL25102056 | 0.83 | HRH3 (0.47) | HRH3ALDH1A1 | |
| SCHEMBL8278776 | 0.82 | SLC6A5 (0.49) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL13207164 | 0.81 | EPHX2 (0.50) | CA1CA2CA12CA9KDM5A | |
| SCHEMBL23166300 | 0.79 | CA1 (0.40) | HRH3CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283263-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2020160193-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160196-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160198-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-7459450-B2 | Neuropeptide receptor modulators | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459450-B2 | Neuropeptide receptor modulators | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7368457-B2 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | SCHERING CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 789/4885ALDH1A1 4012/4885CYP2D6 3159/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 278/4885ALDH1A1 2742/4885CYP2D6 2438/4885 |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | HRH3 3035/4885ALDH1A1 619/4885CYP2D6 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.